Personal tools

9. Neuroscience & Imaging Colloquium – Advances in Imaging of Neuromyelitis Optica Spectrum Disorders (NMOD)

Oct 18, 2017 from 04:30 PM to 05:30 PM
DINZ Seminarraum 1.158/9, Haus 19, Fetscherstraße 74, 01307 Dresden
DINZ Seminarraum 1.158/9, Haus 19, Fetscherstraße 74, 01307 Dresden
Contact Name
Hagen Kitzler
Contact Email
Add event to calendar

Shannon Kolind, PhD
Assistant Professor, MRI Physicist, Division of Neurology, Department of Medicine University of British Columbia, Vancouver BC Canada

Inflammatory demyelinating lesions of the central nervous system are a common feature of both neuromyelitis optica (NMO) and multiple sclerosis (MS). Despite this similarity, it is evident clinically that the accumulation of disability in patients with NMO is relapse related and that a progressive phase is very uncommon. This poses the question whether there is any pathological evidence of disease activity or neurodegeneration in neuromyelitis optica between relapses. To investigate this we have conducted a series of studies investigating diffuse changes in NMO and MS brain and spinal cord. In particular, we have used myelin-specific MRI to characterise changes in both diseases in brain and spinal cord normal appearing and lesional tissue. I will present results of longitudinal measurements over one year, as well as relationships between structural changes and clinical scores.

Dr. Shannon Kolind earned her PhD in Physics at UBC developing myelin water imaging and its application to the study of multiple sclerosis (MS). She then completed a postdoctoral fellowship at FMRIB (University of Oxford) as well as the Institute of Psychiatry, King's College London. While in the UK, she specialised in developing new methods to image myelin using MRI, and making them more practical for use in research. She then returned to UBC, this time in the Division of Neurology, to become an Assistant Professor. Shannon's lab is focused on developing a toolbox of tissue-specific imaging techniques. Her multi-disciplinary team employs these multi-modal tools to achieving greater sensitivity and specificity in clinical research; particularly for clinical trials of new therapies.